The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Fixed-duration epcoritamab with BR for 1L treatment of FL: 3-year results from EPCORE NHL-2 arm 3
Umberto Vitolo, MD, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, briefly discusses the 3-year results from arm 3 of the EPCORE NHL-2 trial (NCT04663347), which investigated the combination of epcoritamab with bendamustine-rituximab (BR) as a first-line (1L) treatment for follicular lymphoma (FL). The addition of epcoritamab to the standard BR regimen resulted in a high response rate with a manageable safety profile, and Prof. Vitolo notes that further studies of this combination are now needed to confirm its efficacy. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This was a study involving a patient with follicular lymphoma at first diagnosis that analyzed the combination of epcoritamab plus rituximab-bendamustine. Rituximab-bendamustine is the standard of care in first line follicular lymphoma. With the aim of the study was to show if the adding epcoritamab to rituximab-bendamustine resulted in a higher response rate. That is true because in 26 patients, so the study is small, but all patients but one responded, and the safety profile of the combination was not different from the safety that we usually see with a single component, I mean, bendamustine rituximab or epcoritamab...
This was a study involving a patient with follicular lymphoma at first diagnosis that analyzed the combination of epcoritamab plus rituximab-bendamustine. Rituximab-bendamustine is the standard of care in first line follicular lymphoma. With the aim of the study was to show if the adding epcoritamab to rituximab-bendamustine resulted in a higher response rate. That is true because in 26 patients, so the study is small, but all patients but one responded, and the safety profile of the combination was not different from the safety that we usually see with a single component, I mean, bendamustine rituximab or epcoritamab. And of course, this is only a phase two study and we need to develop this combination that appears a possible alternative for treatment for follicular lymphoma because in follicular lymphoma we have different treatment possibilities, and the combination with bispecific antibodies in first line may improve the CR rate and progression-free survival in these patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
